Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

McMaster News

McMaster News

Infectious Disease

It’s the fifth anniversary of the COVID-19 pandemic and McMaster researchers are developing a better vaccine, using AI to power drug discovery, and sharing evidence-based ways to protect the health of communities and the economy.

Heeding the lessons of COVID-19 in the face of avian influenza

Bird flu has been causing a flurry of human infections, especially in U.S. cattle workers. If the virus learns to spread effectively from human to human, it could change the course of history. Even though our weary world already feels maxed out, we have to make room to avert yet another crisis.

Matthew S Miller, Executive Director, Global Nexus and M.G. DeGroote Institute for Infectious Disease Research, McMaster University

 

A stock photo of a virus under a microscope.

McMaster researchers discover new class of antibiotics

Researcher Gerry Wright, left, and postdoctoral fellow Manoj Jangra, holding a 3D-printed model of lariocidin, the new antibiotic that they discovered together.

Nearly three decades after the last time a new class of antibiotics reached the market, McMaster researchers have made a breakthrough discovery that could hold the key to addressing antimicrobial resistance.

A team led by researcher Gerry Wright has identified a strong candidate to challenge some of the most drug-resistant bacteria on the planet: a new class of antibiotics called lariocidin.

The discovery could address a critical need for new antimicrobial medicines, as bacteria and other microorganisms evolve new ways to withstand existing drugs. AMR is one of the top global public health threats, and Wright says discovering new drugs is a key part of the solution.

Information Box Group

Drug discovery and biomanufacturing hub

Meet our experts

Want to learn more?

Sign up to receive future communications from McMaster University